Beta-tubulin III expression in prostate cancer

References

• Luduena RF, Banerjee A. The isotypes of tubulin: distribution and functional significance. Cancer drug discovery and development: the role of microtubules in cell biology, neurobiology, and oncology. Totowa, NJ: Humana Press; 2008. p 123–75.
   Google Scholar
• Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998;391:199–203.
   PubMed Web of Science ®Google Scholar
• Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) 2010;67:214–23.
   PubMed Web of Science ®Google Scholar
• Katsetos CD, Draberova E, Legido A, Dumontet C, Draber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol 2009;221:505–13.
   PubMed Web of Science ®Google Scholar
• Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168–75.
   PubMed Web of Science ®Google Scholar
• Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001–7.
   PubMed Web of Science ®Google Scholar
• Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007;13:994–9.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584–9.
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282–93.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer 2001;85:735–40.
   PubMed Web of Science ®Google Scholar
• Lu Q, Ludueña RF. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem 1994;269:2041–7.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 1990;265:1794–9.
   PubMed Web of Science ®Google Scholar
• Laing N, Dahllof B, Hartley-Asp B, Ranganathan S, Tew KD. Interaction of estramustine with tubulin isotypes. Biochemistry 1997;36:871–8.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Luduena RF. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 1991;266:1689–91.
   PubMed Web of Science ®Google Scholar
• Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008;7:2070–9.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774–9.
   PubMed Web of Science ®Google Scholar
• Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356–63.
   PubMed Web of Science ®Google Scholar
• Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298–305.
   PubMed Web of Science ®Google Scholar
• Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481–6.
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005;65:141–50.
   PubMed Web of Science ®Google Scholar
• Ather MH, Abbas F, Faruqui N, Israr M, Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008;8:21.
   PubMedGoogle Scholar
• Li Y, Chen HQ, Chen MF, Liu HZ, Dai YQ, Lv H, Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Sci 2009;84:882–7.
   PubMed Web of Science ®Google Scholar
• Mancuso A, Oudard S, Sternberg CN. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007;61:176–85.
   PubMed Web of Science ®Google Scholar
• Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005:20–33.
   PubMedGoogle Scholar
• Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005:34–63.
   PubMedGoogle Scholar
• Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888–93.
   PubMed Web of Science ®Google Scholar
• Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219–22.
   PubMed Web of Science ®Google Scholar
• Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissiere-Michot F, Maille P, Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009;101:951–6.
   PubMed Web of Science ®Google Scholar
• Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007;110:1248–54.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009;8:17–25.
   PubMed Web of Science ®Google Scholar
• Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3´ flanking region. Gene 2008;409:100–8.
   PubMed Web of Science ®Google Scholar
• Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 2009;66:378–88.
   PubMed Web of Science ®Google Scholar
• Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003;55:77–96.
   PubMed Web of Science ®Google Scholar
• Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology 2006;68:2–8.
   PubMedGoogle Scholar
• Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37–44.
   PubMed Web of Science ®Google Scholar